Information from the Infant Bacterial Therapeutics Capital markets day 2017

Infant Bacterial Therapeutics has today, on 8 september, had a capital markets day for investors, analysts and media in Stockholm.

The purpose of the capital markets day was to present the Infant Bacterial Therapeutics and its activities relating to the disease necrotiserande enterocolit (IBP-9414-project) and the disease gastroschisis (IBP-1016-project).

Staffan Strömberg, ceo of Infant Bacterial Therapeutics, announced that the company has all the data from the phase II safety and toleransstudie (NCT02472769) on the company’s leading drug candidate, IBP-9414, and that the results will be communicated when analysis of data is complete.

The presentation provided during the equity market-day is available on the company’s website:

If the Infant Bacterial Therapeutics AB

Infant Bacterial Therapeutics AB (publ) (“IBT”) is a pharmaceutical company with a vision to develop drugs that affect the infant microbiome, and thereby be able to prevent or treat rare diseases that affect premature babies. By using his vast experience of treatment with living bacteria, and its well-developed know-how of the Lactobacillus reuteris mechanisms of action, develop IBT its leading drug candidate IBP-9414 for the prevention of necrotizing enterocolitis (NEC), a deadly, rare disease that affects premature babies.

The FDA and EUROPEAN commission have granted särläkemedelsstatus, and the FDA has granted a “Rare Pediatric Disease”-the status of the IBP-9414 for the prevention of NEC.

IBT is also working with a second program for a rare disease with a non satisfied medical need gastroschisis, a very serious disease that affects infants. Through the development of these drugs has the IBT the opportunity to satisfy medical needs where there currently are no available treatments.

IBT is listed on Nasdaq First North Premier with Erik Penser Bank as Certified Adviser.

For more information, please contact the

Staffan Strömberg, CEO

Infant Bacterial Therapeutics AB

Bryggargatan 10

111 21 Stockholm

Telephone: +46 8 410 145 55

PR 20170908 CMD update ENG

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Infant Bacterial Therapeutics AB via Globenewswire